LUNG (Pulmonx) Total Liabilities: $74.21 Mil (As of Mar. 2026)


LUNG Pulmonx Corp LUNG
49 GF Score
Price $1.39
GF Value $7.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pulmonx Total Liabilities?

Pulmonx LUNG -5.44% 49 Total Liabilities is $74.21 Mil as of Mar. 2026. GuruFocus rates LUNG with a GF Score™ of 49/100 and a GF Value™ of $7.13 (Possible Value Trap). The stock has 6 warning signs investors should review.

Pulmonx's Total Liabilities for the quarter that ended in Mar. 2026 was $74.21 Mil.

Pulmonx's quarterly Total Liabilities declined from Sep. 2025 ($78.25 Mil) to Dec. 2025 ($75.18 Mil) and declined from Dec. 2025 ($75.18 Mil) to Mar. 2026 ($74.21 Mil).

Pulmonx's annual Total Liabilities increased from Dec. 2023 ($59.47 Mil) to Dec. 2024 ($77.04 Mil) but then declined from Dec. 2024 ($77.04 Mil) to Dec. 2025 ($75.18 Mil).

Pulmonx Total Liabilities Historical Data

* Premium members only.

The historical data trend for Pulmonx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmonx Total Liabilities Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 41.93 39.67 59.47 77.04 75.18

Pulmonx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.07 78.10 78.25 75.18 74.21
LUNG
49GF Score
Pulmonx Corp LUNG
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmonx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pulmonx's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=20.058+(55.048+-4.4964032497319E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.069+0+0)
=75.18

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=129.291-54.116
=75.18

Pulmonx's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.906+(54.95+0.277
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.072+0+0)
=74.21

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=119.966-45.761
=74.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $74.21 Mil mean?
Pulmonx (LUNG) has a Total Liabilities of $74.21 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pulmonx and its competitors.
Is Pulmonx's Total Liabilities too high?
Pulmonx's current Total Liabilities is $74.21 Mil. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Total Liabilities compare to MDAI and QTI?
Pulmonx's Total Liabilities of $74.21 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pulmonx and its competitors. Pulmonx's current Total Liabilities is $74.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.39 — trading 80.5% below its estimated fair value. The current Total Liabilities is $74.21 Mil. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pulmonx (LUNG), the current Total Liabilities is $74.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulmonx (LUNG) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of $1.39 is trading 80.5% below its estimated GF Value™ of $7.13. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for LUNG:

  • Total Liabilities: $74.21 Mil
  • GF Value™: $7.13 vs. price of $1.39 (80.5% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pulmonx Business Description

Other Exchanges 4NI:Germany
Address 700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score

Get the complete analysis for LUNG

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$7.13
GF Value